Skip to main content
    D

    DiaMedica Therapeutics Inc (DMAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.38
    +0.05 (+0.60%)

    Market Cap: $449.47M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    DiaMedica Therapeutics Inc (DMAC) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    DiaMedica Therapeutics (DMAC) has a market cap of $449.47M and an enterprise value of $442.67M. Revenue fell 100.20% over the last 12 months from the 12 months before. Its share count is up 8.69% from a year earlier.

    Total Valuation

    Enterprise value is 1.51% below the market cap, as cash exceeds debt.

    Market Cap$449.47M
    Enterprise Value$442.67M
    Latest price (Nov 17, 2026)$8.38

    Key Dates

    The next earnings report is expected on Mar 29, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 29, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.09% in the quarter ended Sep 30, 2026 and grew 12.33% a year over 2 years.

    Shares Outstanding53.94M
    Shares Change (YoY)+8.69%
    Shares Change (QoQ)+0.09%
    Share Count Growth (2Y CAGR)+12.33%

    Price Statistics

    The stock is up 41.32% over 52 weeks and trades 1.33% above its 50-day average.

    Beta (1Y)1.83
    52-Week Change+41.32%
    1-Month Change+6.48%
    3-Month Change+23.05%
    6-Month Change+50.45%
    5-Year Change+134.18%
    10-Year Change+134.53%
    Total Return (1Y)+41.32%
    Total Return (3Y CAGR)+49.84%
    Total Return (5Y CAGR)+17.97%
    Return vs SPY (1Y)+9.89%
    Max Drawdown (1Y)-43.24%
    Max Drawdown (3Y)-49.17%
    Sharpe Ratio (1Y)0.34
    Correlation with SPY (1Y)0.44
    50-Day Average$8.27
    200-Day Average$7.18
    52-Week Range$5.25 to $11.00
    RSI (14 Days)44.5
    Average Volume (20 Days)217.94K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.76x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.76x
    Quick Ratio4.76x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -140.38% over the last 12 months, against a 5-year average of -46.05%.

    Return on Equity (ROE)-140.38%
    Return on Assets (ROA)-111.28%
    Return on Capital Employed (ROCE)-140.07%
    ROE (5Y Average)-46.05%
    ROA (5Y Average)-42.30%
    ROIC (5Y Average)-58.35%

    Scores

    DMAC has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was -$28.00K over the last 12 months.

    Revenue-$28.00K
    Revenue Growth (YoY)-100.20%
    Gross Profit-$14.00K
    Operating Income-$41.81M
    Pretax Income-$40.20M
    Net Income-$40.23M
    EBIT-$40.20M
    Reported EPS (TTM)-$0.76

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 79.28% of the $36.15M in total assets.

    Cash and Equivalents$6.80M
    Total Debt$0
    Net Cash$6.80M
    Net Cash Per Share$0.13
    Working Capital$28.04M
    Shareholder Equity$28.66M
    Book Value Per Share$0.53
    Total Assets$36.15M
    Total Liabilities$7.49M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $27.00K of capital spending, operating cash flow left -$33.82M of free cash flow.

    Operating Cash Flow-$33.79M
    Capital Expenditures$27.00K
    Free Cash Flow-$33.82M
    FCF Per Share-$0.63
    Depreciation and Amortization$804.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-5.77%
    Tangible Book Per Share Growth (2Y CAGR)-5.77%

    Revenue and profit by year

    Dividends and Yields

    DMAC does not pay a dividend. Its free cash flow yield is -7.48%.

    FCF Yield-7.48%
    Buyback Yield-2.59%
    Shareholder Yield-2.59%

    Stock Splits

    The last split was a 1-for-20 reverse split on Nov 15, 2018.

    Last Split DateNov 15, 2018
    Split TypeReverse split
    Split Ratio1:20

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About DMAC

    What is DMAC's market cap?

    DiaMedica Therapeutics has a market cap of $449.47M. Its enterprise value, which adds debt and subtracts cash, is $442.67M.

    How many shares of DMAC are outstanding?

    DiaMedica Therapeutics has 53.94M shares outstanding. The count is up 8.69% from a year earlier.

    Does DMAC pay a dividend?

    No. DiaMedica Therapeutics does not pay a dividend.

    How much debt does DMAC have?

    DiaMedica Therapeutics has $0 of total debt and $6.80M of cash and equivalents, a net cash position of $6.80M.